In early March the Journal of the American Medical Association (JAMA) estimated the populationprevalence of HPV infection in American women aged 14 to 59 years old. What the CDC study authors found was an overall prevalence of HPV (anytype) infection in 26.8 percent of the American females studied, with 3.4 percent infected with one of the four HPV types in Merck's quadrivalent vaccineand 2 percent infected with one of the two vaccine types (HPV 16 and 18) associated with cervical cancer.
The study noted that 90 percent of allHPV infections are cleared from the body and do not become chronic. This means that less than one quarter of one percent of all American women are at risk for chronic infection with one of the two HPV types associated with cervical cancer which are contained in Merck's Gardasilvaccine.
These new HPV prevalence data seriously call into question the cost benefit ratio for Gardasil, particularly when taking into account short- and long-term serious vaccine reactions being reported to the Vaccine Adverse Event Reporting System (VAERS), such as five cases of GuillainBarre Syndrome (GBS) and cases of syncope with seizures, facial paralysis and other signs of brain and immune system dysfunction. The editorial in JAMA also questioned whether the two HPV types in the vaccine would be replaced by the other HPV types associated with cervical cancer, limiting the vaccine's effectiveness. On May 18, 2006, the FDA staff questioned this possibility.
The Washington Times reports that ACIP chairman Jon Abramson and other committee members did not want Gardasil mandated. If this is true, then ACIP should have stated that fact clearly when they made their recommendation in the summer of 2006 that all eleven-year-old girls get the vaccine. In light of newly published HPV prevalence data and the fact that Merck only studied Gardasil in a few hundred eleven-year-old girls for a few years, together with reports of serious adverse events such as GBS coming into VAERS, the CDC's ACIP members should be more worried about unanimously recommending GARDASIL for routine use with inadequate supporting evidence.
This is worth repeating...there have already been five cases of GBS, and the vaccine was only tested on a few hundred girls.
Despite the growing list of outstanding scientific questions about the vaccine's necessity, safety and effectiveness. All we see is knee-jerk endorsements of school mandates for this vaccine. American children should not be viewed as guinea pigs by drug companies, health officials, doctors, or politicians.
Kenneth Stoller, MD, FAAP
Santa Fe, New Mexico
Mar 21 2007 - 9:44am